Solid Biosciences to Participate at The Citizens Life Sciences Conference
Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its upcoming participation in The Citizens Life Sciences Conference.
The company's President and CEO, Bo Cumbo, will engage in a fireside chat scheduled for Wednesday, May 7, at 12:30 pm ET. Interested parties can access the presentation through a live webcast available on the Events page of the company's Investors section website.
Key Details:
- Event: The Citizens Life Sciences Conference
- Format: Fireside Chat
- Date & Time: May 7, 12:30 pm ET
- Replay Availability: 30-day archive access
Institutional investors seeking management meetings during the conference are advised to contact their Citizens representative.
Solid Biosciences (Nasdaq: SLDB), un'azienda nel settore delle scienze della vita specializzata nello sviluppo di terapie genetiche di precisione per malattie neuromuscolari e cardiache, ha annunciato la sua prossima partecipazione alla Citizens Life Sciences Conference.
Il Presidente e CEO della società, Bo Cumbo, parteciperà a una conversazione informale prevista per mercoledì 7 maggio alle 12:30 ET. Gli interessati potranno seguire la presentazione tramite una diretta web disponibile nella sezione Eventi del sito dedicato agli Investitori della società.
Dettagli principali:
- Evento: Citizens Life Sciences Conference
- Formato: Conversazione informale
- Data e ora: 7 maggio, 12:30 ET
- Disponibilità della replica: accesso all'archivio per 30 giorni
Gli investitori istituzionali che desiderano organizzare incontri con il management durante la conferenza sono invitati a contattare il proprio rappresentante Citizens.
Solid Biosciences (Nasdaq: SLDB), una empresa de ciencias de la vida enfocada en desarrollar medicamentos genéticos de precisión para enfermedades neuromusculares y cardíacas, ha anunciado su próxima participación en The Citizens Life Sciences Conference.
El Presidente y CEO de la compañía, Bo Cumbo, participará en una charla informal programada para el miércoles 7 de mayo a las 12:30 pm ET. Las personas interesadas podrán acceder a la presentación a través de una transmisión en vivo disponible en la página de Eventos de la sección de Inversores del sitio web de la compañía.
Detalles clave:
- Evento: The Citizens Life Sciences Conference
- Formato: Charla informal
- Fecha y hora: 7 de mayo, 12:30 pm ET
- Disponibilidad de repetición: acceso al archivo por 30 días
Se recomienda a los inversionistas institucionales que deseen reuniones con la gerencia durante la conferencia que contacten a su representante de Citizens.
Solid Biosciences (나스닥: SLDB)은 신경근육 및 심장 질환을 위한 정밀 유전자 치료제를 개발하는 생명과학 회사로서, 다가오는 Citizens Life Sciences Conference에 참여할 예정임을 발표했습니다.
회사의 사장 겸 CEO Bo Cumbo는 5월 7일 수요일 오후 12시 30분(동부 시간)에 예정된 파이어사이드 채팅에 참여할 예정입니다. 관심 있는 분들은 회사 투자자 섹션 내 이벤트 페이지에서 라이브 웹캐스트를 통해 발표를 시청할 수 있습니다.
주요 내용:
- 행사명: Citizens Life Sciences Conference
- 형식: 파이어사이드 채팅
- 일시: 5월 7일, 오후 12:30 ET
- 재방송 이용 가능 기간: 30일간 아카이브 접근
회의 기간 동안 경영진과의 미팅을 원하는 기관 투자자는 Citizens 담당자에게 연락하시기 바랍니다.
Solid Biosciences (Nasdaq : SLDB), une entreprise des sciences de la vie spécialisée dans le développement de médicaments génétiques de précision pour les maladies neuromusculaires et cardiaques, a annoncé sa prochaine participation à la Citizens Life Sciences Conference.
Le président-directeur général de la société, Bo Cumbo, participera à une discussion informelle prévue le mercredi 7 mai à 12h30 ET. Les personnes intéressées pourront accéder à la présentation via une diffusion en direct disponible sur la page Événements de la section Investisseurs du site web de la société.
Détails clés :
- Événement : Citizens Life Sciences Conference
- Format : Discussion informelle
- Date et heure : 7 mai, 12h30 ET
- Disponibilité du replay : accès à l’archive pendant 30 jours
Les investisseurs institutionnels souhaitant organiser des réunions avec la direction lors de la conférence sont invités à contacter leur représentant Citizens.
Solid Biosciences (Nasdaq: SLDB), ein Life-Sciences-Unternehmen, das sich auf die Entwicklung präziser genetischer Therapien für neuromuskuläre und kardiale Erkrankungen spezialisiert hat, hat seine bevorstehende Teilnahme an der Citizens Life Sciences Conference angekündigt.
Der Präsident und CEO des Unternehmens, Bo Cumbo, wird an einem Fireside-Chat teilnehmen, der für Mittwoch, den 7. Mai, um 12:30 Uhr ET geplant ist. Interessierte können die Präsentation über einen Live-Webcast auf der Veranstaltungsseite im Investor-Bereich der Unternehmenswebsite verfolgen.
Wichtige Details:
- Veranstaltung: Citizens Life Sciences Conference
- Format: Fireside Chat
- Datum & Uhrzeit: 7. Mai, 12:30 Uhr ET
- Wiederholungszugang: 30 Tage Archivzugang
Institutionelle Investoren, die während der Konferenz Managementgespräche wünschen, werden gebeten, ihren Citizens-Ansprechpartner zu kontaktieren.
- CEO participation in a major life sciences conference indicates strong institutional visibility
- None.
CHARLESTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, at 12:30 pm ET.
A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 30 days on the Events page.
Institutional investors interested in meeting with management during the conference may reach out to their Citizens representative.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
When is Solid Biosciences (SLDB) presenting at The Citizens Life Sciences Conference 2025?
How can investors watch Solid Biosciences' (SLDB) Citizens Conference presentation?
What type of medicines is Solid Biosciences (SLDB) developing in 2025?
How can institutional investors meet with Solid Biosciences (SLDB) management at the Citizens Conference?
What is the format of Solid Biosciences' (SLDB) presentation at the Citizens Life Sciences Conference?
